Entrada Therapeutics: First Participant Dosed in Phase 1 Clinical Trial of ENTR-601-44

Entrada Therapeutics has dosed its first participant in their Phase 1 clinical trial of ENTR-601-44 for Duchenne muscular dystrophy.

The EMA’s human medicines committee (CHMP) has recommended not to renew the Marketing Authorization for Translarna (ataluren), a medicine for treating patients with Duchenne muscular dystrophy (DMD).

Italfamaraco has submitted the Marketing Authorization Application (MAA) for Givinostat as a potential treatment for Duchenne muscular dystrophy to the European Medicine Agency (EMA) and that the EMA has started its regulatory review process.

FibroGen has announced topline results of the Phase 3 LELANTOS-2 trial of pamrevlumab, their investigational anti-fibrotic monoclonal antibody, for ambulatory patients with Duchenne muscular dystrophy.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to AOC 1044, an experimental exon 44-skipping therapy for Duchenne muscular dystrophy.

Edgewise Therapeutics has provided an updated on Duchenne and Becker muscular dystrophy clinical trials.

The FDA has granted Orphan Drug Designation to NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy.

Casimir is currently recruiting Canadians with Duchenne for their ARISE remote study evaluating the performance of the Duchenne Video Assessment (DVA) tool to assess quality of movement in Duchenne.

PepGen has released their Q2 Newsletter, including an update for the Canadian Duchenne muscular dystrophy community regarding the CONNECT1-ED051 clinical trial.

Italfarmaco has completed the FDA submission of New Drug Application (NDA) for Givinostat in Duchenne muscular dystrophy and receives priority review.